Breast cancer poses a significant global health challenge and includes various subtypes, such as endocrine-positive, HER2-positive, and triple-negative. Endocrine-positive breast cancer, characterized by estrogen and progesterone receptors, is commonly treated with aromatase inhibitors. However, resistance to these inhibitors can hinder patient outcomes due to genetic and epigenetic alterations, mutations in the estrogen receptor 1 gene, and changes in signaling pathways. Radiogenomics combines imaging techniques like MRI and CT scans with genomic profiling methods to identify radiographic biomarkers associated with resistance. This approach enhances our understanding of resistance mechanisms and metastasis patterns, linking them to specific genomic profiles and common metastasis sites like the bone and brain. By integrating radiogenomic data, personalized treatment strategies can be developed, improving predictive and prognostic capabilities. Advancements in imaging and genomic technologies offer promising avenues for enhancing radiogenomic research. A thorough understanding of resistance mechanisms is crucial for developing effective treatment strategies, making radiogenomics a valuable integrative approach in personalized medicine that aims to improve clinical outcomes for patients with metastatic endocrine-positive breast cancer.
乳腺癌是全球面临的重大健康挑战，包含多种亚型，如内分泌阳性、HER2阳性和三阴性。内分泌阳性乳腺癌以雌激素和孕激素受体为特征，通常采用芳香化酶抑制剂治疗。然而，由于遗传和表观遗传改变、雌激素受体1基因突变以及信号通路变化，患者可能对这些抑制剂产生耐药性，从而影响治疗效果。放射基因组学将MRI和CT等影像技术与基因组分析方法相结合，以识别与耐药相关的影像学生物标志物。这种方法有助于我们深入理解耐药机制和转移模式，并将其与特定的基因组特征及常见转移部位（如骨骼和大脑）联系起来。通过整合放射基因组数据，可以制定个性化治疗策略，从而提高预测和预后能力。影像学和基因组技术的进步为加强放射基因组学研究提供了广阔前景。深入了解耐药机制对于制定有效治疗策略至关重要，这使得放射基因组学成为个性化医疗中一种有价值的整合方法，旨在改善转移性内分泌阳性乳腺癌患者的临床结局。
肿瘤(癌症)患者之家